Table 1:

Use of cell-free fetal DNA screening and prenatal diagnostic testing in singleton pregnancies by level of risk for trisomy 21 based on multiple-marker screening

Multiple-marker screening risk for trisomy 21	Before cffDNA screening funded*; rate of uptake, %			After cffDNA screening funded†; rate of uptake, %
	cffDNA screening	Prenatal diagnostic testing	cffDNA screening or prenatal diagnostic testing	cffDNA screening	Prenatal diagnostic testing	cffDNA screening or prenatal diagnostic testing
≥ 1:10	4.0	67.5	70.2	30.5	54.1	76.1
1:11–1:50	6.1	63.1	67.8	44.3	40.5	78.8
1:51–1:100	8.0	55.9	62.6	51.1	29.2	77.3
1:101–1:200	6.4	50.9	56.3	55.1	23.5	76.3
1:201–1:350	3.1	13.1	15.9	25.2	6.0	29.9
1:351–1:500	1.4	6.4	7.5	12.5	2.3	14.6
1:501–1:1000	1.1	4.1	5.2	9.3	1.6	10.6
1:1000–1:5000	0.6	2.0	2.6	5.3	1.0	6.2
< 1:5000	0.2	0.7	0.9	2.0	0.5	2.4
All risk groups‡	0.6	3.3	3.8	5.0	1.9	6.6

Note: cffDNA = cell-free fetal DNA.

^*Expected date of delivery between July 2012 and June 2014.

^†Expected date of delivery between July 2014 and March 2016.

^‡All risk groups plus no multiple-marker screening result.